CSF metabolic and proteomic profiles in patients prodromal for psychosis.
BACKGROUND: The initial prodromal state of psychosis (IPS) is defined as an early disease stage prior to the onset of overt psychosis characterized by sub-threshold or more unspecific psychiatric symptoms. Little is known regarding the biochemical changes during this period. METHODOLOGY/PRINCIPAL FI...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2007-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC1942084?pdf=render |
| _version_ | 1818152891206074368 |
|---|---|
| author | Jeffrey T-J Huang F Markus Leweke Tsz M Tsang Dagmar Koethe Laura Kranaster Christoph W Gerth Sonja Gross Daniela Schreiber Stephan Ruhrmann Frauke Schultze-Lutter Joachim Klosterkötter Elaine Holmes Sabine Bahn |
| author_facet | Jeffrey T-J Huang F Markus Leweke Tsz M Tsang Dagmar Koethe Laura Kranaster Christoph W Gerth Sonja Gross Daniela Schreiber Stephan Ruhrmann Frauke Schultze-Lutter Joachim Klosterkötter Elaine Holmes Sabine Bahn |
| author_sort | Jeffrey T-J Huang |
| collection | DOAJ |
| description | BACKGROUND: The initial prodromal state of psychosis (IPS) is defined as an early disease stage prior to the onset of overt psychosis characterized by sub-threshold or more unspecific psychiatric symptoms. Little is known regarding the biochemical changes during this period. METHODOLOGY/PRINCIPAL FINDINGS: We investigated the metabolic/proteomic profiles of cerebrospinal fluid (CSF) of first-onset drug naïve paranoid schizophrenia patients (n = 54) and individuals presenting with initial prodromal symptoms (n = 24), alongside healthy volunteers (n = 70) using proton nuclear magnetic resonance ((1)H-NMR) spectroscopy and surface enhanced laser desorption ionization (SELDI) mass spectrometry, respectively. Partial least square discriminant analysis (PLS-DA) showed that 36%/29% of IPS patients displayed proteomic/metabolic profiles characteristic of first-onset, drug naïve schizophrenia, i.e., changes in levels of glucose and lactate as well as changes in a VGF-derived peptide (VGF23-62) and transthyretin protein concentrations. However, only 29% (n = 7) of the investigated IPS patients (who to date have been followed up for up to three years) have so far received a diagnosis of schizophrenia. The presence of biochemical alterations in the IPS group did not correlate with the risk to develop schizophrenia. CONCLUSIONS/SIGNIFICANCE: Our results imply that schizophrenia-related biochemical disease processes can be traced in CSF of prodromal patients. However, the biochemical disturbances identified in IPS patients, at least when measured at a single time point, may not be sufficient to predict clinical outcome. |
| first_indexed | 2024-12-11T14:01:55Z |
| format | Article |
| id | doaj.art-f6a9aae8d688456fb433348f6c376a7d |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-11T14:01:55Z |
| publishDate | 2007-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-f6a9aae8d688456fb433348f6c376a7d2022-12-22T01:03:50ZengPublic Library of Science (PLoS)PLoS ONE1932-62032007-01-0128e75610.1371/journal.pone.0000756CSF metabolic and proteomic profiles in patients prodromal for psychosis.Jeffrey T-J HuangF Markus LewekeTsz M TsangDagmar KoetheLaura KranasterChristoph W GerthSonja GrossDaniela SchreiberStephan RuhrmannFrauke Schultze-LutterJoachim KlosterkötterElaine HolmesSabine BahnBACKGROUND: The initial prodromal state of psychosis (IPS) is defined as an early disease stage prior to the onset of overt psychosis characterized by sub-threshold or more unspecific psychiatric symptoms. Little is known regarding the biochemical changes during this period. METHODOLOGY/PRINCIPAL FINDINGS: We investigated the metabolic/proteomic profiles of cerebrospinal fluid (CSF) of first-onset drug naïve paranoid schizophrenia patients (n = 54) and individuals presenting with initial prodromal symptoms (n = 24), alongside healthy volunteers (n = 70) using proton nuclear magnetic resonance ((1)H-NMR) spectroscopy and surface enhanced laser desorption ionization (SELDI) mass spectrometry, respectively. Partial least square discriminant analysis (PLS-DA) showed that 36%/29% of IPS patients displayed proteomic/metabolic profiles characteristic of first-onset, drug naïve schizophrenia, i.e., changes in levels of glucose and lactate as well as changes in a VGF-derived peptide (VGF23-62) and transthyretin protein concentrations. However, only 29% (n = 7) of the investigated IPS patients (who to date have been followed up for up to three years) have so far received a diagnosis of schizophrenia. The presence of biochemical alterations in the IPS group did not correlate with the risk to develop schizophrenia. CONCLUSIONS/SIGNIFICANCE: Our results imply that schizophrenia-related biochemical disease processes can be traced in CSF of prodromal patients. However, the biochemical disturbances identified in IPS patients, at least when measured at a single time point, may not be sufficient to predict clinical outcome.http://europepmc.org/articles/PMC1942084?pdf=render |
| spellingShingle | Jeffrey T-J Huang F Markus Leweke Tsz M Tsang Dagmar Koethe Laura Kranaster Christoph W Gerth Sonja Gross Daniela Schreiber Stephan Ruhrmann Frauke Schultze-Lutter Joachim Klosterkötter Elaine Holmes Sabine Bahn CSF metabolic and proteomic profiles in patients prodromal for psychosis. PLoS ONE |
| title | CSF metabolic and proteomic profiles in patients prodromal for psychosis. |
| title_full | CSF metabolic and proteomic profiles in patients prodromal for psychosis. |
| title_fullStr | CSF metabolic and proteomic profiles in patients prodromal for psychosis. |
| title_full_unstemmed | CSF metabolic and proteomic profiles in patients prodromal for psychosis. |
| title_short | CSF metabolic and proteomic profiles in patients prodromal for psychosis. |
| title_sort | csf metabolic and proteomic profiles in patients prodromal for psychosis |
| url | http://europepmc.org/articles/PMC1942084?pdf=render |
| work_keys_str_mv | AT jeffreytjhuang csfmetabolicandproteomicprofilesinpatientsprodromalforpsychosis AT fmarkusleweke csfmetabolicandproteomicprofilesinpatientsprodromalforpsychosis AT tszmtsang csfmetabolicandproteomicprofilesinpatientsprodromalforpsychosis AT dagmarkoethe csfmetabolicandproteomicprofilesinpatientsprodromalforpsychosis AT laurakranaster csfmetabolicandproteomicprofilesinpatientsprodromalforpsychosis AT christophwgerth csfmetabolicandproteomicprofilesinpatientsprodromalforpsychosis AT sonjagross csfmetabolicandproteomicprofilesinpatientsprodromalforpsychosis AT danielaschreiber csfmetabolicandproteomicprofilesinpatientsprodromalforpsychosis AT stephanruhrmann csfmetabolicandproteomicprofilesinpatientsprodromalforpsychosis AT fraukeschultzelutter csfmetabolicandproteomicprofilesinpatientsprodromalforpsychosis AT joachimklosterkotter csfmetabolicandproteomicprofilesinpatientsprodromalforpsychosis AT elaineholmes csfmetabolicandproteomicprofilesinpatientsprodromalforpsychosis AT sabinebahn csfmetabolicandproteomicprofilesinpatientsprodromalforpsychosis |